AVANIR PHARMACEUTICALS
10-K405, EX-27.1, 2000-12-21
PHARMACEUTICAL PREPARATIONS
Previous: AVANIR PHARMACEUTICALS, 10-K405, EX-23.1, 2000-12-21
Next: CISCO SYSTEMS INC, 8-K, 2000-12-21



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S FORM 10-K FOR THE TWELVE MONTHS ENDED SEPTEMBER 30, 2000 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-START>                             OCT-01-1999
<PERIOD-END>                               SEP-30-2000
<CASH>                                      19,699,768
<SECURITIES>                                         0
<RECEIVABLES>                                   95,429
<ALLOWANCES>                                         0
<INVENTORY>                                      9,804
<CURRENT-ASSETS>                            21,085,474
<PP&E>                                       1,625,208
<DEPRECIATION>                                 574,505
<TOTAL-ASSETS>                              23,519,237
<CURRENT-LIABILITIES>                        1,922,929
<BONDS>                                              0
                                0
                                    465,920
<COMMON>                                    84,729,735<F1>
<OTHER-SE>                                (63,599,347)<F2>
<TOTAL-LIABILITY-AND-EQUITY>                23,519,237
<SALES>                                        225,353
<TOTAL-REVENUES>                            10,687,026
<CGS>                                          261,603
<TOTAL-COSTS>                                  261,603
<OTHER-EXPENSES>                            10,491,418<F3>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             516,288
<INCOME-PRETAX>                              (582,283)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (582,283)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (582,283)
<EPS-BASIC>                                   (0.02)
<EPS-DILUTED>                                   (0.02)
<FN>
<F1>INCLUDES CLASS A COMMON STOCK OF $84,695,590 AND CLASS B COMMON STOCK OF
$34,145.
<F2>INCLUDES SUBSCRIPTION RECEIVABLE FOR CLASS A COMMON STOCK OF $649,431.
<F3>INCLUDES LITIGATION SETTLEMENT COSTS OF $4.1 MILLION PAID WITH SHARES OF
COMMON STOCK.
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission